Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biomedical companies. Prospect Venture Partners would make investments of $3 million to $5 million apiece in early- and late-stage companies, including public companies. Target ... David Schnell is a seasoned venture capital investor and Managing Director at Prospect Venture Partners, specializing in biotechnology.
📞 6503278800
🔒 Sign up for free to view key contact information
Sign up free →This profile has not yet been verified by the firm. Information may be incomplete or outdated. Claim this profile to take control of your listing.
Claim this profile to complete your information, set investment criteria, and start receiving curated deal flow from sponsors on DEALITHIC.